Meratrim® is a 100% natural, patented botanical composition that supports healthy body weight management, metabolism and benefits cardiovascular health.
Meratrim® is supported by three independent, randomized, double-blind, placebo- controlled studies conducted in healthy, overweight to obese men and women. Gold standard scientific research has established the clinical efficacies of Meratrim®.
These clinical studies, conducted in two hundred and twenty adults, demonstrated that a daily dose of 800 mg of Meratrim® significantly reduced the body weight and BMI of the participants. Also, Meratrim® supplementation helped to reduce central obesity as measured by the waist-hip ratio, improved serum lipid profile, and insulin sensitivity, increased the serum adiponectin levels, and resulted in a better quality of life for the participants. Notably, the outcomes on safety parameters in these human trials and a broad spectrum of pre-clinical safety studies, including genotoxicity studies, suggest that Meratrim® supplementation is a tolerable and safe ingredient for human consumption
In addition to reducing adipogenesis and increasing fat breakdown, Meratrim® also activates the master metabolic regulator AMP–activated protein kinase (AMPK) enzyme and reduced the enzyme expression of de novo fat synthesis in the fat cells, and positively modulated the critical factors of endothelial functions.
Meratrim® is clinically proven to help reduce body weight overall.
Toxicological studies on Meratrim® have demonstrated a wide margin of safety. In vitro studies demonstrated that Meratrim® modulates the expression of biomarkers that control adipogenesis and lipogenesis as follows:
Perilipins are adipocyte proteins that are localized at the surface of the lipid droplet and inhibit fat breakdown by restricting access of lipase to the lipid droplet.
Applications
Reducing belly fat is always a hot topic, so when Dr Oz talks about it – we are happy to share the news.
Dr Oz introduces fascinating and frequently cutting-edge health and nutrition information on his show – and we like that he and his staff look for topics backed by legitimate science.
His February 10th show, “Triple Your Fat Loss”, got attention.
Dr Oz revealed a new ingredient called Meratrim® , clinically shown to significantly reduce belly and hip fat within two weeks – without using stimulants or caffeine.
Dr Oz had 30 audience members try this new Meratrim® fat fighting “fruit and flower combination.” These participants followed a generous 2,000–calorie diet and walked for 30 minutes a day, five days a week. These were the same conditions in the clinical trials of Meratrim® . Dr Oz reported that the average audience member lost three inches in their waistlines in only two weeks.
As summarized by Dr Oz, Meratrim® helps users lose fat inches by:
Reduces Obesity by inhibiting Fat synthesis and increasing Fat burning
Turns on Master Metabolic switch - AMPK
Maintains Healthy blood pressure by improving endothelial function
Improves Blood glucose levels
Enhances Serum Lipid profile
The 56 Day Randomized Double- Blind Placebo-Controlled Study
Meratrim® Reduces Body Weight in Obese Subjects
Bar diagram represents net reduction in body weight. * P< 0.05 and ** p < 0.01
Meratrim® Reduces BMI in Obese Subjects
Bar diagram represents net reduction in BMI. * P< 0.05 and * * p < 0.01
Meratrim® Improves Serum Adiponectin
Bar diagram represents mean serum adiponectin levels
The serum adiponectin level in Meratrim® supplemented group on day 56 is 28.4% better when compared placebo.
Efficacy of Meratrim® in Modulating Biochemical Parameters
Bar diagram represents modulation of different biochemical parameters * p< 0.05
Significant reduction in TG & considerable reduction in serum glucose and cholesterol
The 56 Day Randomized Double Blind Placebo Controlled Study
Meratrim® Reduces Body Weight in Obese Subjects
Bar diagram represents net reduction in body weight. * P< 0.05 and ** p < 0.01
Clinical Study II: Meratrim® Reduces BMI in Obese Subjects
Bar diagram represents net reduction in BMI. * P< 0.05 and ** p < 0.01
Meratrim® in Modulating Serum Adiponectin and PAI-1
Bar diagram represents mean serum adiponectin and PAI-1 levels, * p< 0.05
NOTE: Plasminogen Activator Inhibitor-1 (PAI-1) is a principal inhibitor of tissue plasminogen activator and urokinase,
the activators of fibrinolysis (physiological breakdown of blood clots)
Meratrim® in Modulating Biochemical Parameters
Bar diagram represents modulation of different biochemical parameters, * p< 0.05
Significant reductions in serum triglycerides, glucose, cholesterol and LDL/HDL were observed in subjects supplemented with Meratrim®
The 112 Day Randomized Double Blind Placebo Controlled Study in Overweight Subjects
Meratrim® Reduces Body Weight in Overweight Subjects
Bar diagram represents net reduction in body weight. * P< 0.05 (ANCOVA)
Meratrim® in Reducing BMI in Overweight Subjects
Bar diagram represents net reduction in BMI. * P< 0.05 and ** p < 0.01 (ANCOVA)
Meratrim® in Modulating Serum Adiponectin
Bar diagram represents mean serum adiponectin levels
Meratrim® showed improvement in serum adiponectin whereas placebo showed reduction in Adiponectin levels.
Meratrim® Reduces Mood Disturbance
Bar diagram represents modulation of different biochemical parameters, * p< 0.05 , by ANCOVA using baseline as covariate
Toxicity studies conducted following the OECD test guidelines.
The acute oral LD50 for Meratrim® in Sprague Dawley rats is > 5000 mg/kg. Its human equivalent dose is > 48000 mg, which is more than 60-fold higher than the recommended daily human dose (800 mg).
(Non mutagenic up to 5000 µg/plate)
(Non mutagenic up to 2000 mg/kg)
(Non mutagenic up to 5000 µg/plate)
Meratrim® exhibited synergistic efficacy on body weight reduction in comparison against individual ingredients.
Bar diagrammatic representation of % reduction in body weight in diet induced obese model of Sprague Dawley rats. The bars 1 to 5 represent % reductions in body weight in treatment groups supplemented with Ingredient 1(100 and 250 mg/kg), Ingredient 2 (250 mg/kg), Meratrim® (250 mg/kg) and sibutramine (7 mg/kg) respectively.
Bar diagrammatic representation of % increase in serum adiponectin concentration in diet induced obese model of Sprague Dawley rats. The bars 1 to 5 represent % reductions in body weight in treatment groups supplemented with Ingredient 1(100 and 250 mg/kg), Ingredient 2 (250 mg/kg), Meratrim® (250 mg/kg) and sibutramine (7 mg/kg) respectively.
Meratrim® potently reduces body weight gain in diet induced obese model of Sprague Dawley rats
Bar diagrammatic representation of % reduction in body weight of DIO rats supplemented with different test substances compared to control group . The bars 1 to 4 represent groups supplemented with Ingredient 1(250 mg/kg), Ingredient 2 (250 mg/kg), Meratrim® (250 mg/kg) and sibutramine (7mg/kg) respectively.
Meratrim® dose dependently enhances lipolysis in 3T3-L1 fat cells. Intracellular Fat breakdown (lipolysis)
was estimated based on the amount of glycerol released in the culture medium.
Photomicrographs show Perilipin localization on the membrane of lipid vesicles in adipocytes. Immunofluorescence intensities in A and B specifically demonstrate perilipin coat of lipid vesicles in vehicle (0.2% DMSO) and Meratrim® (10 µg/ml) treated 3T3-L1 adipocytes, respectively. Arrows show localization of perilipin.
Meratrim® Activates cAMP Activated Protein Kinase (AMPK)
Meratrim® turns on metabolic master switch AMPK, regulating cellular glucose uptake, β-oxidation of fat, biogenesis of glucose transporter (GLUT-4). Hence, Meratrim® raises a strong possibility for developing a therapeutic strategy against metabolic disorders
Meratrim® Down Regulates Fatty Acid Synthase Expression in Fat Cells
Meratrim® inhibits de novo lipogenesis in fat cells
Meratrim® Induces Nitrite Production in Human Primary Endothelial Cells
Meratrim® helps in increasing Nitric oxide surge in capillary endothelial cells via
eNOS activation through its hyper-phosphorylation. This suggests that Meratrim® might improve endothelial function.
Meratrim® Inhibits Production of Cellular Adhesion Proteins in Human Primary Endothelial cells
Meratrim® inhibits production of ICAM-1 and VCAM-1 in IL-1β induced human endothelial cells; hence, providing further support in improving endothelial function.
The Food and Drug Administration has not evaluated statements on this website. The products are not intended to diagnose, treat, cure or prevent disease. This website’s technical content and claims are for business information purposes only. Your legal counsel should review them before use in marketing materials, including product labels. Some of these statements may not apply to your markets or regulations since they are intended for various geographies worldwide.